OTCMKTS:BIOVF Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BIOVF Stock Alerts $25.76 +2.89 (+12.62%) (As of 05/3/2024) Add Compare Share Share Today's Range$25.41▼$25.7650-Day Range$22.87▼$27.7952-Week Range$18.35▼$27.79Volume4,000 shsAverage Volume750 shsMarket CapitalizationN/AP/E Ratio42.93Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Swedish Orphan Biovitrum AB (publ) alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More BIOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOVF Stock News HeadlinesMay 8, 2024 | finance.yahoo.comSobi has completed SEK 3 billion senior bond issueMay 7, 2024 | americanbankingnews.comSwedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Shares Up 12.6%May 13, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.May 6, 2024 | uk.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (SOBI.ST)April 27, 2024 | seekingalpha.comSwedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call TranscriptApril 26, 2024 | finance.yahoo.comSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia AApril 25, 2024 | msn.comSwedish Orphan Biovitrum AB reports Q1 resultsApril 25, 2024 | finance.yahoo.comSobi Q1 2024 report: Strong sales reflecting the strength of the portfolioMay 13, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.April 24, 2024 | markets.businessinsider.comSwedish Orphan Biovitrum AB earnings: here's what to expectApril 4, 2024 | prnewswire.comNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)April 2, 2024 | finance.yahoo.comSobi publishes Annual and sustainability report for 2023February 20, 2024 | au.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (SWOBY)February 8, 2024 | finance.yahoo.comSobi publishes Q4 2023 report: Strong revenue performance and growth into 2024February 3, 2024 | realmoney.thestreet.comSwedish Orphan Biovitrum price target raised to SEK 385 at RBC CapitalFebruary 1, 2024 | finance.yahoo.comAll You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong BuyJanuary 24, 2024 | finance.yahoo.comInvitation: Sobi's Q4 and FY 2023 reportJanuary 5, 2024 | finance.yahoo.comSobi's Chairman of the Board resigns due to health reasonsNovember 30, 2023 | finance.yahoo.comChange in number of shares and votes in Swedish Orphan Biovitrum AB (publ)November 23, 2023 | morningstar.comSwedish Orphan Biovitrum AB BIOVFNovember 1, 2023 | finance.yahoo.comSobi has completed the issuances of series C sharesOctober 30, 2023 | msn.comSwedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17BOctober 30, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss EstimatesOctober 30, 2023 | finance.yahoo.comSobi publishes Q3 2023 report: Strong revenue and solid performanceOctober 27, 2023 | finance.yahoo.comReminder: Invitation: Sobi's Q3 2023 reportOctober 18, 2023 | finance.yahoo.comInvitation: Sobi's Q3 2023 reportSeptember 15, 2023 | finance.yahoo.comReminder: Sobi KOL investor event: Advancing the standard of care in haemophiliaSee More Headlines Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/12/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CUSIPN/A CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,612Year Founded2001Profitability EPS (Most Recent Fiscal Year)$0.60 Trailing P/E Ratio42.93 Forward P/E RatioN/A P/E GrowthN/ANet Income$227.17 million Net Margins9.29% Pretax Margin13.35% Return on Equity8.20% Return on Assets3.52% Debt Debt-to-Equity Ratio0.34 Current Ratio0.66 Quick Ratio0.46 Sales & Book Value Annual Sales$2.09 billion Price / SalesN/A Cash Flow$1.90 per share Price / Cash Flow13.53 Book Value$10.82 per share Price / Book2.38Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.53 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Guido Oelkers (Age 59)CEO & President Comp: $25.82MMr. Henrik Stenqvist (Age 57)Chief Financial Officer Mr. Torbjörn Hallberg (Age 55)General Counsel & Head of Legal Affairs Mr. Daniel Rankin (Age 44)Head of Strategy & Corporate Development Ms. Lena Bjurner (Age 56)Head of Human Resources Mr. Armin Reininger M.D. (Age 67)Ph.D., Senior Scientific & Medical Advisor Mr. Norbert Oppitz (Age 57)Head of International Mr. Sofiane Fahmy (Age 52)Head of Europe Mr. Duane H. Barnes (Age 64)Head of North America Mr. Mahmood Ladha (Age 60)Head of Strategic Transformation Operations More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFView All Competitors BIOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks. How have BIOVF shares performed in 2024? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the start of the year. Since then, BIOVF shares have decreased by 1.9% and is now trading at $25.7557. View the best growth stocks for 2024 here. Are investors shorting Swedish Orphan Biovitrum AB (publ)? Swedish Orphan Biovitrum AB (publ) saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,162,200 shares, an increase of 48.9% from the April 15th total of 780,600 shares. Based on an average daily trading volume, of 600 shares, the days-to-cover ratio is presently 1,937.0 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest. When is Swedish Orphan Biovitrum AB (publ)'s next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BIOVF earnings forecast. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) released its earnings results on Thursday, April, 25th. The company reported $0.26 EPS for the quarter. The firm had revenue of $601.91 million for the quarter. Swedish Orphan Biovitrum AB (publ) had a net margin of 9.29% and a trailing twelve-month return on equity of 8.20%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOVF) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityElon’s New Device is About to Shock the WorldInvestorPlaceThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.